Literature DB >> 23889334

Missing data in alcohol clinical trials: a comparison of methods.

Kevin A Hallgren1, Katie Witkiewitz.   

Abstract

BACKGROUND: The rate of participant attrition in alcohol clinical trials is often substantial and can cause significant issues with regard to the handling of missing data in statistical analyses of treatment effects. It is common for researchers to assume that missing data is indicative of participant relapse, and under that assumption, many researchers have relied on setting all missing values to the worst-case scenario for the outcome (e.g., missing = heavy drinking). This sort of single-imputation method has been criticized for producing biased results in other areas of clinical research, but has not been evaluated within the context of alcohol clinical trials, and many alcohol researchers continue to use the missing = heavy drinking assumption.
METHODS: Data from the COMBINE study, a multisite randomized clinical trial, were used to generate simulated situations of missing data under a variety of conditions and assumptions. We manipulated the sample size (n = 200, 500, and 1,000) and dropout rate (5, 10, 25, 30%) under 3 missing data assumptions (missing completely at random, missing at random, and missing not at random). We then examined the association between receiving naltrexone and heavy drinking during the first 10 weeks following treatment using 5 methods for treating missing data (complete case analysis [CCA], last observation carried forward [LOCF], missing = heavy drinking, multiple imputation [MI], and full information maximum likelihood [FIML]).
RESULTS: CCA, LOCF, and missing = heavy drinking produced the most biased naltrexone effect estimates and standard errors under conditions that are likely to exist in randomized clinical trials. MI and FIML produced the least biased naltrexone effect estimates and standard errors.
CONCLUSIONS: Assuming that missing = heavy drinking produces biased results of the treatment effect and should not be used to evaluate treatment effects in alcohol clinical trials.
Copyright © 2013 by the Research Society on Alcoholism.

Entities:  

Keywords:  Alcohol Use Disorder; Clinical Trials; Missing Data; Relapse; Treatment

Mesh:

Substances:

Year:  2013        PMID: 23889334      PMCID: PMC4113114          DOI: 10.1111/acer.12205

Source DB:  PubMed          Journal:  Alcohol Clin Exp Res        ISSN: 0145-6008            Impact factor:   3.455


  33 in total

1.  Accounting for dropout bias using mixed-effects models.

Authors:  C H Mallinckrodt; W S Clark; S R David
Journal:  J Biopharm Stat       Date:  2001 Feb-May       Impact factor: 1.051

2.  Handling drop-out in longitudinal clinical trials: a comparison of the LOCF and MMRM approaches.

Authors:  Peter Lane
Journal:  Pharm Stat       Date:  2008 Apr-Jun       Impact factor: 1.894

3.  MMRM vs. LOCF: a comprehensive comparison based on simulation study and 25 NDA datasets.

Authors:  Ohidul Siddiqui; H M James Hung; Robert O'Neill
Journal:  J Biopharm Stat       Date:  2009       Impact factor: 1.051

4.  MMRM versus MI in dealing with missing data--a comparison based on 25 NDA data sets.

Authors:  Ohidul Siddiqui
Journal:  J Biopharm Stat       Date:  2011-05       Impact factor: 1.051

5.  The characteristics of alcoholics frequently lost to follow-up.

Authors:  A Mackenzie; F R Funderburk; R P Allen; R L Stefan
Journal:  J Stud Alcohol       Date:  1987-03

Review 6.  Measurement of drinking behavior using the Form 90 family of instruments.

Authors:  W R Miller; F K Del Boca
Journal:  J Stud Alcohol Suppl       Date:  1994-12

7.  Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.

Authors:  Raymond F Anton; Stephanie S O'Malley; Domenic A Ciraulo; Ron A Cisler; David Couper; Dennis M Donovan; David R Gastfriend; James D Hosking; Bankole A Johnson; Joseph S LoCastro; Richard Longabaugh; Barbara J Mason; Margaret E Mattson; William R Miller; Helen M Pettinati; Carrie L Randall; Robert Swift; Roger D Weiss; Lauren D Williams; Allen Zweben
Journal:  JAMA       Date:  2006-05-03       Impact factor: 56.272

8.  A double-blind, placebo-controlled trial assessing the efficacy of levetiracetam extended-release in very heavy drinking alcohol-dependent patients.

Authors:  Joanne B Fertig; Megan L Ryan; Daniel E Falk; Raye Z Litten; Margaret E Mattson; Janet Ransom; William J Rickman; Charles Scott; Domenic Ciraulo; Alan I Green; Nassima A Tiouririne; Bankole Johnson; Helen Pettinati; Eric C Strain; Eric Devine; Mary F Brunette; Kyle Kampman; David A Tompkins; Robert Stout
Journal:  Alcohol Clin Exp Res       Date:  2012-02-10       Impact factor: 3.455

9.  The impact of loss to follow-up on hypothesis tests of the treatment effect for several statistical methods in substance abuse clinical trials.

Authors:  Sarra L Hedden; Robert F Woolson; Rickey E Carter; Yuko Palesch; Himanshu P Upadhyaya; Robert J Malcolm
Journal:  J Subst Abuse Treat       Date:  2008-11-13

10.  Stereotyping and the treatment of missing data for drug and alcohol clinical trials.

Authors:  Stephan Arndt
Journal:  Subst Abuse Treat Prev Policy       Date:  2009-02-18
View more
  63 in total

1.  Tests of linear and nonlinear relations between cumulative contextual risk at birth and psychosocial problems during adolescence.

Authors:  Gilbert R Parra; Gail L Smith; W Alex Mason; Jukka Savolainen; Mary B Chmelka; Jouko Miettunen; Marjo-Riitta Järvelin
Journal:  J Adolesc       Date:  2017-07-26

2.  Mindfulness-Based Relapse Prevention and Transcranial Direct Current Stimulation to Reduce Heavy Drinking: A Double-Blind Sham-Controlled Randomized Trial.

Authors:  Katie Witkiewitz; Elena R Stein; Victoria R Votaw; Adam D Wilson; Corey R Roos; Stevi J Gallegos; Vincent P Clark; Eric D Claus
Journal:  Alcohol Clin Exp Res       Date:  2019-05-09       Impact factor: 3.455

3.  Integrated stepped alcohol treatment for patients with HIV and alcohol use disorder: a randomised controlled trial.

Authors:  E Jennifer Edelman; Stephen A Maisto; Nathan B Hansen; Christopher J Cutter; James Dziura; Yanhong Deng; Lynn E Fiellin; Patrick G O'Connor; Roger Bedimo; Cynthia L Gibert; Vincent C Marconi; David Rimland; Maria C Rodriguez-Barradas; Michael S Simberkoff; Janet P Tate; Amy C Justice; Kendall J Bryant; David A Fiellin
Journal:  Lancet HIV       Date:  2019-05-17       Impact factor: 12.767

4.  Short- and long-term changes in substance-related coping as mediators of in-person and computerized CBT for alcohol and drug use disorders.

Authors:  Corey R Roos; Kathleen M Carroll; Charla Nich; Tami Frankforter; Brian D Kiluk
Journal:  Drug Alcohol Depend       Date:  2020-05-12       Impact factor: 4.492

Review 5.  -Omic and Electronic Health Record Big Data Analytics for Precision Medicine.

Authors:  Po-Yen Wu; Chih-Wen Cheng; Chanchala D Kaddi; Janani Venugopalan; Ryan Hoffman; May D Wang
Journal:  IEEE Trans Biomed Eng       Date:  2016-10-10       Impact factor: 4.538

6.  Social network moderators of naltrexone and behavioral treatment effects on heavy drinking in the COMBINE study.

Authors:  Matthew J Worley; Katie Witkiewitz; Sandra A Brown; Daniel R Kivlahan; Richard Longabaugh
Journal:  Alcohol Clin Exp Res       Date:  2015-01       Impact factor: 3.455

7.  Combining seeking safety with sertraline for PTSD and alcohol use disorders: A randomized controlled trial.

Authors:  Denise A Hien; Frances Rudnick Levin; Lesia M Ruglass; Teresa López-Castro; Santiago Papini; Mei-Chen Hu; Lisa Renee Cohen; Abigail Herron
Journal:  J Consult Clin Psychol       Date:  2015-01-26

8.  What happens when people discontinue taking medications? Lessons from COMBINE.

Authors:  Robert L Stout; Jordan M Braciszewski; Meenakshi Sabina Subbaraman; Henry R Kranzler; Stephanie S O'Malley; Daniel Falk
Journal:  Addiction       Date:  2014-09-12       Impact factor: 6.526

Review 9.  Guidelines for the Reporting of Treatment Trials for Alcohol Use Disorders.

Authors:  Katie Witkiewitz; John W Finney; Alex H S Harris; Daniel R Kivlahan; Henry R Kranzler
Journal:  Alcohol Clin Exp Res       Date:  2015-08-11       Impact factor: 3.455

Review 10.  Recommendations for the Design and Analysis of Treatment Trials for Alcohol Use Disorders.

Authors:  Katie Witkiewitz; John W Finney; Alex H S Harris; Daniel R Kivlahan; Henry R Kranzler
Journal:  Alcohol Clin Exp Res       Date:  2015-08-06       Impact factor: 3.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.